Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGR | P09769 | 1/20 | 0.54 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.54 |
| ▸ | TXK | P42681 | 1/20 | 0.54 |
| ▸ | FRK | P42685 | 1/20 | 0.54 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.54 |
| ▸ | EIF2AK3 | Q9NZJ5 | 6/20 | 0.53 |
| ▸ | SRC | P12931 | 3/20 | 0.49 |
| ▸ | TEK | Q02763 | 2/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.49 |
| ▸ | ABL1 | P00519 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | ABL2 | P42684 | 2/20 | 0.49 |
| ▸ | NEK7 | Q8TDX7 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2074338 | 0.93 | EIF2AK3 (0.53) | EIF2AK3SRCTEKLCKRIPK2 | |
| SCHEMBL6459150 | 0.91 | EIF2AK3 (0.52) | EIF2AK3TEKRIPK2NEK7 | |
| SCHEMBL6461797 | 0.88 | TEK (0.64) | PTK6EIF2AK3SRCTEKLCK | |
| SCHEMBL30527006 | 0.88 | TEK (0.64) | PTK6EIF2AK3SRCTEKLCK | |
| SCHEMBL14183076 | 0.88 | TEK (0.64) | PTK6EIF2AK3SRCTEKLCK | |
| SCHEMBL6461798 | 0.88 | TEK (0.64) | PTK6EIF2AK3SRCTEKLCK | |
| SCHEMBL6460401 | 0.87 | EIF2AK3 (0.49) | EIF2AK3SRCTEKLCKRIPK2 | |
| SCHEMBL2074412 | 0.87 | EGFR (0.54) | EIF2AK3SRCTEKLCKRIPK2 | |
| SCHEMBL2074616 | 0.86 | EIF2AK3 (0.54) | EIF2AK3SRCTEKLCKRIPK2 | |
| SCHEMBL6460593 | 0.84 | EIF2AK3 (0.58) | FGREPHA1TXKFRKPTK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| WO-2004100868-A2 | METHOD OF TREATING TRANSPLANT REJECTION | ABBOTT LABORATORIES (US) | 2004-11-25 | — | — | WO | disclosed |
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
| WO-2001072751-A1 | PYRROLOPYRIMIDINES AS TYROSINE KINASE INHIBITORS | KNOLL GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | FGR 334/4885EPHA1 1497/4885TXK 492/4885 |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | FGR 283/4885EPHA1 2762/4885TXK 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.